Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia

Key facts

Sponsor

Medical University of Graz

Principal Investigator

Gerda Trutnovsky, MD

Medical University of Graz

Intervention

Imiquimod(drug)

Enrollment

110 target

Eligibility

18-90 years · FEMALE

Timeline

2013 – 2021

Study locations (9)

• Dep. of Gynecology, Krankenhaus Barmherzige Brüder Graz, Graz, Styria, Austria
• Dep. of Gynecology and Obstetrics, Landes Frauen- und Kinderklinik Linz, Linz, Upper Austria, Austria
• Department of Obstetrics and Gynecology/ Medical University of Graz, Graz, Austria
• Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria
• Dep. of Gynecology and Obstetrics, Klinikum Klagenfurt, Klagenfurt, Austria
• Dep. of Gynecology and Obstetrics, Leoben, Austria
• Dep. of Gynecology, Krankenhaus Barmherzige Schwestern Linz, Linz, Austria
• Dep. of Gynecology and Obstetrics, Landeskrankenhaus Salzburg, Salzburg, Austria
• Department of General Gynecology and Gynecology Oncology, Medical University of Vienna, Vienna, Austria

Collaborators

Austrian Science Fund (FWF)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.